The correlation of serum HER-2/ neuand CA15-3 in patients with metastatic breast cancer

Journal of Breast Cancer

Volumn 11, Issue 1, 2008, Pages 18-24

  Park, Nae Kyeong ^a   Woo, Hee Doo ^a   Sohn, Doo Min ^a   Kim, Sung Yong ^a   Lim, Cheol Wan ^a   Choi, Tae Youn ^a   Kim, Jae Jun ^a   Lee, Min Hyuk ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

CA15 3; Extracellular domain (ECD); Metastatic breast cancer; Primary breast cancer; Serum HER 2 neu

Indexed keywords

CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIMARY TUMOR; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; TUMOR VOLUME;

EID: 70350641143     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2008.11.1.18     Document Type: Article

References (40)

1. Korean Breast Cancer Society. Nationwide Korean breast cancer data 2002. J Breast Cancer 2004;7:72-83.
2. Michael JD. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-351
3. Bates SE. Clinical applications of serum tumour markers. Ann Intern Med 1991;115:623-638
4. Beastall GH, Cook B, Rustin GJ, Jennings J. A review of the role of established tumour markers. Ann Clin Biochem 1991;28:5-18.
5. Gang Y, Adachi I, Okhura H, Yamomoto H, Mizuguchi Y, Abe K. CA15-3 is present as a novel tumour marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho 1985;12:2379-2386(English abstract).
6. Tomlinson IP, Whyman A, Barrett JA, Kremer JK. Tumour marker CA15-3: possible use in the routine management of breast cancer. Eur J Cancer 1995;31A:899-902.
7. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-2877
8. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230 (Pubitemid 16128785)
9. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139 (Pubitemid 16169997)
10. Kim JW, Kim SY, Lee HS, Woo HD, Son DM, Lim CW, et al. Establishment for reference range of serum HER-2/neu in Korean healthy women. J Breast Cancer 2006;9:301-308
11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71. (Pubitemid 24345325)
12. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-1675
13. Yoo KY, Tajima K, Kuroishi T, Hirose K, Yoshida M, Miura S, et al. Independent protective effect of lactation against breast cancer: a case-control study in Japan. Am J Epidemiol 1992;135:726-733
14. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer(1). N Engl J Med 1992;327:319-328
15. Gunczler P, Ogris E, Maca S, Danmayr E. Tumour markers in breast cancer: on the diagnostic value of serum determinations in clinical freedom from tumour and manifest disease. Onkologie 1989;12:209-214(English abstract).
16. Suzuki S. Early diagnosis for bone metastases of breast cancer based on bone metabolism. Fukushima J Med Sci 1990;36:11-27.
17. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-264 (Pubitemid 11149660)
18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
19. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002;8:475-486 (Pubitemid 36342270)
20. Storm FK, Gilchrist KW, Warner TF, Mahvi DM. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas. Ann Surg Oncol 1995;2:43-48
21. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865-871
22. Brandt-Rauf PW, Monaco R, Pincus MR. Conformation of the transmembrane domain of the epidermal growth factor receptor. J Protein Chem 1994;13:227-231 (Pubitemid 24135986)
23. Gullick WJ, Bottomley AC, Lofts FJ, Doak DG, Mulvey D, Newman R, et al. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J 1992;11:43-48
24. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201-208 (Pubitemid 19062410)
25. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 2000;7:158-166
26. Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997;54:475-481 (Pubitemid 27470258)
27. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-119 (Pubitemid 38849881)
28. Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz JP, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005;51:1093-1101 (Pubitemid 43079384)
29. Kim SY, Kim TY, Kim JJ, Kim CH, Song OP, Lee MH, et al. Clinical correlation of HER-2/neu overexpression in patients with breast cancer. J Korean Breast Cancer Society 2004;7:244-250
30. Toikanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-1048
31. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-476
32. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349
33. Noh DY, Choe KJ, Kim JP, Park IA, Park SH, Yoo KY. DNA ploidy, S-phase activity and c-erbB-2 oncogene protein expression in breast cancer and its relationship to prognosis. J Korean Cancer Association 1992;24:73-81.
34. Han SH, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997;65: 22-27
35. Gsaparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 1992;66:970-976
36. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992;164:323-326 (Pubitemid 23005184)
37. Park W, Paik NS, Kim YK, Moon NM, Lee JI, Choi DW, et al. The expression of c-erbB-2 oncoprotein and epidermal growth factor receptor (EGFR) in breast cancer patients in Korea. J Korean Cancer Association 1994;26:901-911
38. Luftner D, Cheli C, Mickelson K, Sampson E, Possinger K. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers 2004;19:175-182 (Pubitemid 39406238)
39. Luftner D, Luke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem 2003;36:233-240 (Pubitemid 36700452)
40. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum HER-2/neu and serum CA15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314-1320 (Pubitemid 34809841)